ONL Therapeutics | Advancing Retinal Disease Therapies through Neuroprotection

News

ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science

December 9, 2025
ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025

November 10, 2025
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD

October 28, 2025
ONL Therapeutics Announces Multiple Presentations at Leading Ophthalmology Meetings

February 4, 2025
ONL Therapeutics Appoints Penny Fleck as Chief Development Officer

January 7, 2025
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

September 13, 2024
ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight

September 10, 2024
ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference

February 6, 2024
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society

January 23, 2024

Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2025